Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
Nanomedicine (Lond). 2014 Apr;9(4):535-54. doi: 10.2217/nnm.13.223.
The research on porous silicon (PSi) materials for biomedical applications has expanded greatly since the early studies of Leigh Canham more than 25 years ago. Currently, PSi nanoparticles are receiving growing attention from the scientific biomedical community. These nanostructured materials have emerged as promising multifunctional and versatile platforms for nanomedicine in drug delivery, diagnostics and therapy. The outstanding properties of PSi, including excellent in vivo biocompatibility and biodegradability, have led to many applications of PSi for delivery of therapeutic agents. In this review, we highlight current advances and recent efforts on PSi nanoparticles regarding the production properties, efficient drug delivery, multidrug delivery, permeation across biological barriers, biosafety and in vivo tracking for biomedical applications. The constant boost on successful preclinical in vivo data reported so far makes this the 'golden age' for PSi, which is expected to finally be translated into the clinic in the near future.
多孔硅（PSi）材料在生物医学应用方面的研究自 Leigh Canham 二十多年前的早期研究以来有了很大的发展。目前，PSi 纳米颗粒受到了科学界生物医学领域越来越多的关注。这些纳米结构材料已经成为药物输送、诊断和治疗中具有广阔应用前景的多功能和通用的纳米医学平台。PSi 的卓越性能，包括优异的体内生物相容性和生物可降解性，使得 PSi 在治疗剂的输送方面有了许多应用。在这篇综述中，我们重点介绍了 PSi 纳米颗粒在生产特性、高效药物输送、多药物输送、跨生物屏障渗透、生物安全性和体内追踪等方面的最新进展和研究进展。迄今为止，成功的临床前体内数据不断增加，这使得 PSi 迎来了“黄金时代”，预计在不久的将来将最终转化为临床应用。
